Weight & appetite / amylin biology
Zenagamtide vs Cagrilintide
Both involve amylin-family biology but zenagamtide is a unimolecular GLP-1/amylin/calcitonin receptor agonist while cagrilintide is a long-acting amylin.
At a glance
Zenagamtide
Cagrilintide
Human evidence
Two peer-reviewed 2026 Phase II trials show significant HbA1c reductions with once-weekly subcutaneous and once-daily oral zenagamtide in type 2 diabetes.
Cagrilintide has randomized Phase II weight-loss evidence and a Phase IIIa monotherapy arm within REDEFINE 1; cagrilintide 2.4 mg weekly produced roughly 11.5%-11.8% mean weight reduction at 68 weeks depending on estimand.
Research focus
Obesity, type 2 diabetes, sleep apnoea, knee osteoarthritis, heart failure
Obesity, appetite and weight-management research
Regulatory status
Investigational; Phase 3 obesity programme initiated in 2026. No general marketing authorisation identified.
FDA states cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in U.S. compounding under federal law.
Route / formulation
Oral and subcutaneous regimens are formulation-specific and not interchangeable.
Trial evidence does not establish quality or equivalence of research-market material.
No direct head-to-head trial identified Both involve amylin-family biology but zenagamtide is a unimolecular GLP-1/amylin/calcitonin receptor agonist while cagrilintide is a long-acting amylin analogue; evidence maturity differs.